首页> 外文期刊>American Journal of Cancer Research >Screening and diagnosis of colorectal cancer and advanced adenoma by Bionic Glycome method and machine learning
【24h】

Screening and diagnosis of colorectal cancer and advanced adenoma by Bionic Glycome method and machine learning

机译:仿生组合方法和机器学习筛选与诊断结直肠癌和晚期腺瘤

获取原文
           

摘要

Colorectal cancer (CRC), one of the major health problems worldwide, mostly develops from colorectal adenomas. Advanced adenomas are generally considered as precancerous lesions and patients are recommended to remove the adenomas. Screening for colorectal cancer is usually performed by fecal tests (FOBT or FIT) and colonoscopy, however, their benefits are limited by uptake and adherence. Most CRC develops from colorectal advanced adenomas, but there is currently a lack of effective noninvasive screening method for advanced adenomas. N-glycans in human serum hold the great potentials as biomarker for diagnosis of human cancers. Our aim was to discover blood-based markers for screening and diagnosis of advanced adenomas and CRC, and to ascertain their efficiency in classifying healthy controls, patients with advanced adenomas and CRC by incorporating machine learning techniques with reliable and simple quantitative method with “Bionic Glycome” as internal standard based on the high-throughput Matrix-assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS). The quantitative results showed that there is a positive correlation between multi-antennary, sialylated N-glycans and CRC progress, while bi-antennary core-fucosylated N-glycans are negatively correlated with CRC progress. Machine learning is a powerful classification tool, suitable for mining big data, especially the large amount of data generated by high-throughput technologies. Using the predictive model constructed by machine learning, we obtained the classification accuracy of 75% for classification of 189 samples including CRC, advanced adenomas and healthy controls, and the accuracy of 87% for detection of the disease group that required treatment, including CRC and advanced adenomas. To our delight, the model successfully applied to the prediction of 176 samples collected a few months later, and five samples were wrongly predicted in the disease group. Overall, this diagnostic model we constructed here has valuable potential in the clinical application of detecting advanced adenomas and colorectal cancer and could compensate for the limitations of the current screening methods for detection of CRC and advanced adenomas.
机译:结肠直肠癌(CRC)是全世界的主要健康问题之一,主要从结肠直肠腺瘤发展。先进的腺瘤通常被认为是癌前病变,建议患者去除腺瘤。用于结直肠癌的筛选通常通过粪便试验(FOBT或FIT)和结肠镜检查,然而,它们的益处受摄取和粘附的限制。大多数CRC从结肠直肠高级腺瘤发展,但目前缺乏用于高级腺瘤的有效的非侵入性筛选方法。人类血清中的N-聚糖将巨大的潜力作为生物标志物,用于诊断人类癌症。我们的目的是发现基于血液的标记,用于筛查和诊断先进的腺瘤和CRC,并通过将机器学习技术与“仿生Glycome的可靠性定量方法掺入具有可靠和简单的定量方法的机器学习技术来确定健康对照组和CRC的效率。 “作为基于高通量矩阵辅助激光解吸/电离质谱(MALDI-MS)的内标。定量结果表明,多抗长期,唾液酸的N-聚糖和CRC进展之间存在正相关,而双抗长期核 - 岩藻糖基化的N-聚糖与CRC进展负相关。机器学习是一个强大的分类工具,适用于挖掘大数据,尤其是高吞吐量技术产生的大量数据。使用由机器学习构建的预测模型,我们获得了189个样本的分类的分类精度为75%,包括CRC,晚期腺瘤和健康对照,以及87%的准确度检测所需治疗的疾病组,包括CRC和高级腺瘤。为了我们的喜悦,在几个月后成功应用于176个样本的预测的模型,并且在疾病组中预测了五个样品。总的来说,我们在这里构建的这种诊断模型在检测晚期腺瘤和结肠直肠癌的临床应用中具有有价值的潜力,并且可以弥补当前筛选方法检测CRC和晚期腺瘤的局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号